EP3532497A4 - Modifizierte immunoglobulinbandregionen zur verringerung der hämagglutination - Google Patents

Modifizierte immunoglobulinbandregionen zur verringerung der hämagglutination Download PDF

Info

Publication number
EP3532497A4
EP3532497A4 EP17865245.9A EP17865245A EP3532497A4 EP 3532497 A4 EP3532497 A4 EP 3532497A4 EP 17865245 A EP17865245 A EP 17865245A EP 3532497 A4 EP3532497 A4 EP 3532497A4
Authority
EP
European Patent Office
Prior art keywords
hemagglutination
reduce
hinge regions
immunoglobulin hinge
modified immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17865245.9A
Other languages
English (en)
French (fr)
Other versions
EP3532497A1 (de
Inventor
Jie Liu
Irving L. Weissman
Ravindra Majeti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of EP3532497A1 publication Critical patent/EP3532497A1/de
Publication of EP3532497A4 publication Critical patent/EP3532497A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
EP17865245.9A 2016-10-26 2017-10-26 Modifizierte immunoglobulinbandregionen zur verringerung der hämagglutination Pending EP3532497A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413018P 2016-10-26 2016-10-26
PCT/US2017/058569 WO2018081448A1 (en) 2016-10-26 2017-10-26 Modified immunoglobulin hinge regions to reduce hemagglutination

Publications (2)

Publication Number Publication Date
EP3532497A1 EP3532497A1 (de) 2019-09-04
EP3532497A4 true EP3532497A4 (de) 2020-05-13

Family

ID=62025462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17865245.9A Pending EP3532497A4 (de) 2016-10-26 2017-10-26 Modifizierte immunoglobulinbandregionen zur verringerung der hämagglutination

Country Status (3)

Country Link
US (2) US10995152B2 (de)
EP (1) EP3532497A4 (de)
WO (1) WO2018081448A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081448A1 (en) * 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
CA3078253A1 (en) 2017-10-18 2019-04-25 Forty Seven, Inc. Anti-cd47 agent-based ovarian cancer therapy

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175824A1 (en) * 2001-08-17 2004-09-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with high biological activities
WO2008085878A2 (en) * 2007-01-03 2008-07-17 Morphotek, Inc. High affinity antibodies that neutralize staphylcoccus enterotoxin b
WO2011066501A1 (en) * 2009-11-30 2011-06-03 Centocor Ortho Biotech Inc. Antibody fc mutants with ablated effector functions
WO2012075184A2 (en) * 2010-12-02 2012-06-07 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
WO2012151468A1 (en) * 2011-05-05 2012-11-08 Wellstat Immunotherapeutics, Llc Complement factor b analogs and their uses
WO2013109752A1 (en) * 2012-01-17 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University High affinity sirp-alpha reagents
WO2013181253A1 (en) * 2012-05-29 2013-12-05 Regeneron Pharmaceuticals, Inc. Production cell line enhancers
WO2014031687A1 (en) * 2012-08-20 2014-02-27 Jensen, Michael Method and compositions for cellular immunotherapy
WO2014055515A1 (en) * 2012-10-02 2014-04-10 Neurophage Pharmaceuticals, Inc. Use of p3 of bacteriophage fusion proteins as amyloid binding agents
WO2014094122A1 (en) * 2012-12-17 2014-06-26 Trillium Therapeutics Inc. Treatment of cd47+ disease cells with sirp alpha-fc fusions
WO2014102179A1 (en) * 2012-12-27 2014-07-03 Bayer Pharma Aktiengesellschaft Fusion polypeptides and uses thereof
WO2014123580A1 (en) * 2013-02-06 2014-08-14 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN104327187A (zh) * 2014-10-11 2015-02-04 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
WO2015022420A1 (en) * 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2016191305A1 (en) * 2015-05-22 2016-12-01 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
CN1018817B (zh) 1988-12-17 1992-10-28 中国石油化工总公司石油化工科学研究院 具有提高酸性的交联粘土的制备
WO2000068856A2 (en) 1999-05-11 2000-11-16 Webvan Group, Inc. Electronic commerce enabled delivery system and method
US20090000224A1 (en) 2002-02-07 2009-01-01 Bay Industries, Inc. Pultruded door frame
GB0304823D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
US20060204496A1 (en) * 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
JP2005296412A (ja) 2004-04-13 2005-10-27 Olympus Corp 内視鏡治療装置
US8840933B2 (en) 2006-05-03 2014-09-23 Warsaw Orthopedic, Inc. Method of treating neuronal injury by administering magnesium chloride and PEG
US8330550B2 (en) 2006-06-23 2012-12-11 Rgb Systems, Inc. Method and apparatus for automatic compensation of video signal losses from transmission over conductors
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
CA2711938C (en) 2008-01-15 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by cd47
EP4160212B1 (de) 2008-01-15 2024-04-17 The Board of Trustees of the Leland Stanford Junior University Marker für stammzellen der akuten myeloischen leukämie
GB2459509B (en) 2008-04-25 2011-05-11 Goodwin Plc An apparatus for casting and a method of casting
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
EP2477648B1 (de) 2009-09-15 2022-07-20 The Board of Trustees of the Leland Stanford Junior University Synergistische anti-cd47-therapie für blutkrebs
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
JP5628408B2 (ja) 2010-03-24 2014-11-19 トムソン ライセンシングＴｈｏｍｓｏｎ Ｌｉｃｅｎｓｉｎｇ ネットワークのサービス品質を監視する方法及び装置
JP2011216948A (ja) 2010-03-31 2011-10-27 Sony Corp カメラシステム、映像処理装置及びカメラ装置
DK2569013T3 (da) * 2010-05-14 2017-02-13 Univ Leland Stanford Junior Humaniserede og kimære monoklonale antistoffer til cd47
US9183590B2 (en) 2010-07-20 2015-11-10 Neopost Technologies System and method for managing postal accounting data using transient data collectors
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
US20140038485A1 (en) 2011-04-07 2014-02-06 Cargill Incorporated Bio-based binders including carbohydrates and a pre-reacted product of an alcohol or polyol and a monomeric or polymeric polycarboxylic acid
CN103649125A (zh) * 2011-06-22 2014-03-19 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
PL2812443T3 (pl) 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
DE102012103533A1 (de) 2012-04-20 2013-10-24 Köra-Packmat Maschinenbau GmbH Vorrichtung zum Fördern eines Substrats und System zum Bedrucken eines Substrats
KR101910976B1 (ko) 2012-07-16 2018-10-23 삼성전자주식회사 그래핀을 이용한 전계효과 트랜지스터
DE102012213566A1 (de) 2012-08-01 2014-02-06 Robert Bosch Gmbh Verfahren zum Herstellen eines Bondpads zum Thermokompressionsbonden und Bondpad
EP3721888B1 (de) 2013-02-05 2022-07-20 The Board of Trustees of the Leland Stanford Junior University Auf cd47 gerichtete therapien zur behandlung von infektionskrankheiten
EP2970493B1 (de) * 2013-03-15 2019-04-03 The Board of Trustees of the Leland Stanford Junior University Verfahren zur erzielung therapeutisch wirksamer dosierungen von anti-cd47-mitteln
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP2992089B1 (de) 2013-04-29 2021-09-08 The Board of Trustees of the Leland Stanford Junior University Verwendung von anti-cd47-mitteln zur immunisierungserhöhung
WO2014186761A2 (en) 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
US10329354B2 (en) 2013-09-18 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
WO2015105995A2 (en) 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
ES2822561T3 (es) 2014-09-15 2021-05-04 Univ Leland Stanford Junior Direccionamiento a enfermedad por aneurisma modulando las vías de fagocitosis
EP4019040A1 (de) 2015-01-21 2022-06-29 The Board of Trustees of the Leland Stanford Junior University Verwendung von tlr agonisten und anti-cd47 mitteln zur stimulierung der phagozytose von krebszellen
WO2016138306A1 (en) 2015-02-27 2016-09-01 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy for treatment of coronary artery disease
SI3341015T2 (sl) 2015-08-26 2024-03-29 The Board Of Trustees Of The Leland Stanford, Junior University Izboljšana deplecija ciljanih celic z blokado CD47 in imunostimulatornim agonistom
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
CA3005911A1 (en) 2015-12-11 2017-06-15 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of cd47 and egfr
WO2017214096A1 (en) * 2016-06-07 2017-12-14 Macrogenics, Inc. Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders
WO2018081448A1 (en) * 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175824A1 (en) * 2001-08-17 2004-09-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with high biological activities
WO2008085878A2 (en) * 2007-01-03 2008-07-17 Morphotek, Inc. High affinity antibodies that neutralize staphylcoccus enterotoxin b
WO2011066501A1 (en) * 2009-11-30 2011-06-03 Centocor Ortho Biotech Inc. Antibody fc mutants with ablated effector functions
WO2012075184A2 (en) * 2010-12-02 2012-06-07 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
WO2012151468A1 (en) * 2011-05-05 2012-11-08 Wellstat Immunotherapeutics, Llc Complement factor b analogs and their uses
WO2013109752A1 (en) * 2012-01-17 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University High affinity sirp-alpha reagents
WO2013181253A1 (en) * 2012-05-29 2013-12-05 Regeneron Pharmaceuticals, Inc. Production cell line enhancers
WO2014031687A1 (en) * 2012-08-20 2014-02-27 Jensen, Michael Method and compositions for cellular immunotherapy
WO2014055515A1 (en) * 2012-10-02 2014-04-10 Neurophage Pharmaceuticals, Inc. Use of p3 of bacteriophage fusion proteins as amyloid binding agents
WO2014094122A1 (en) * 2012-12-17 2014-06-26 Trillium Therapeutics Inc. Treatment of cd47+ disease cells with sirp alpha-fc fusions
WO2014102179A1 (en) * 2012-12-27 2014-07-03 Bayer Pharma Aktiengesellschaft Fusion polypeptides and uses thereof
WO2014123580A1 (en) * 2013-02-06 2014-08-14 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2015022420A1 (en) * 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
CN104327187A (zh) * 2014-10-11 2015-02-04 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
WO2016191305A1 (en) * 2015-05-22 2016-12-01 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HORGAN CAROL ET AL: "Studies on antigen binding by intact and hinge-deleted chimeric antibodies", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 150, no. 12, 15 June 1993 (1993-06-15), pages 5400 - 5407, XP002423580, ISSN: 0022-1767 *
JIE LIU ET AL: "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential", PLOS ONE, vol. 10, no. 9, 21 September 2015 (2015-09-21), pages 1 - 23, XP055223677, DOI: 10.1371/journal.pone.0137345 *

Also Published As

Publication number Publication date
US20200048369A1 (en) 2020-02-13
EP3532497A1 (de) 2019-09-04
US20210253740A1 (en) 2021-08-19
WO2018081448A1 (en) 2018-05-03
WO2018081448A8 (en) 2024-01-04
US10995152B2 (en) 2021-05-04
US11760810B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
EP3423089A4 (de) Anti-tigit-antikörper
EP3498840A4 (de) Anti-lag-3-antikörper
EP3411412A4 (de) Fabs-in-tandem-immunglobulin und verwendungen davon
EP3481869A4 (de) Anti-cd73-antikörper
EP3387442A4 (de) Humanisierte anti-cd73-antikörper
EP3449940A4 (de) Antikörperhaltiges präparat
EP3204422A4 (de) Humanisierte anti-ox40-antikörper und verwendungen davon
EP3354729A4 (de) Anti-garp-antikörper
EP3363816A4 (de) Anti-ox40-antikörper und verwendungen davon
EP3417133A4 (de) Scharnier
EP3341485A4 (de) Erhöhte produktion von immunglobulinen
EP3526431A4 (de) Scharnieranordnung
EP3532092A4 (de) Immunglobuline und verwendungen davon
EP3380524A4 (de) Humanisierte anti-cll-1-antikörper
EP3252074A4 (de) Anti-alk2-antikörper
EP3492591A4 (de) Anti-b7-h4-antikörper
EP3101131A4 (de) Humanisierte anti-transthyretin-antikörper
EP3411476A4 (de) Erhöhte produktion von immunglobulinen
EP3437776A4 (de) Verbindungsstruktur
EP3507177A4 (de) Motorroller mit klapperschutz
EP3526247A4 (de) Anti-il1-rap-antikörper
EP3457004A4 (de) Dichtungsstruktur
EP3381941A4 (de) Anti-epha4-antikörper
EP3197915A4 (de) Humanisierte anti-hepcidin-antikörper und verwendungen davon
EP3437786A4 (de) Verbindungsstruktur

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190524

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200417

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/19 20060101ALI20200408BHEP

Ipc: C07K 16/18 20060101AFI20200408BHEP

Ipc: C12N 5/10 20060101ALI20200408BHEP

Ipc: C07K 16/28 20060101ALI20200408BHEP

Ipc: C12N 15/85 20060101ALI20200408BHEP

Ipc: G01N 33/53 20060101ALI20200408BHEP

Ipc: C07K 14/705 20060101ALI20200408BHEP

Ipc: C07K 16/46 20060101ALI20200408BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220317

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230711

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240220